Bio-Matrix Scientific Group Enters Into Letter Of Intent For Cancer Vaccine

Bio-Matrix Scientific Group (BMSN) has entered into a Letter of Intent (LOI) with Therinject contemplating the development of a new immuno-therapeutic cancer vaccine.

The LOI, which is subject to the execution of a definitive agreement, contemplates the providing by BMSN of facilities and infrastructure to be utilized by both parties for the development of immuno-therapeutic treatments for cancer.

Initially, BMSN and Therinject plans to focus on the veterinary market, looking to treat animals with tumors while gathering data in support of human clinical trials.

Additionally, Therinject will work with Entest BioMedical’s team to develop intellectual property in this area of cancer treatment, which is anticipated to result in patents being applied for by Entest BioMedical, a majority owned subsidiary of BMSN.

David Koos, chairman and CEO of Bio-Matrix, said: “We see an opportunity to bring this cancer treatment to the veterinary market quickly. The company believes in the first year it will treat roughly 2,000 animals resulting in $3,000 revenue per animal. Essentially allowing the company to generate revenue before entering human clinical trials, while collecting supporting data.”